Literature DB >> 7541587

Physiologic variations of serum testosterone within the normal range do not affect serum prostate-specific antigen.

J R Monath1, D L McCullough, L J Hart, J P Jarow.   

Abstract

OBJECTIVES: To determine the relationship between endogenous total serum testosterone levels and serum prostate-specific antigen (PSA) concentrations. If a correlation exists between these two parameters, then use of testosterone-specific reference ranges may enhance the utility of PSA as a marker for prostate cancer.
METHODS: Data were obtained from 150 men without previous history of prostate cancer. PSA was measured by the Abbott IMX microparticle enzyme immunoassay and total testosterone determined by the Coat-A-Count radioimmunoassay.
RESULTS: No correlation was found between testosterone and PSA, even when corrected for age and weight.
CONCLUSIONS: The data suggest that determination of the total serum testosterone level does not improve the sensitivity or specificity of PSA as a tumor marker.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7541587     DOI: 10.1016/S0090-4295(99)80159-9

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  10 in total

Review 1.  Testosterone deficiency and replacement: Myths and realities.

Authors:  Ethan D Grober
Journal:  Can Urol Assoc J       Date:  2014-07       Impact factor: 1.862

Review 2.  Testosterone Therapy Among Prostate Cancer Survivors.

Authors:  Taylor M Nguyen; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2016-07-27

Review 3.  Testosterone Therapy in Men With Prostate Cancer.

Authors:  Alan L Kaplan; Jim C Hu; Abraham Morgentaler; John P Mulhall; Claude C Schulman; Francesco Montorsi
Journal:  Eur Urol       Date:  2015-12-21       Impact factor: 20.096

Review 4.  Hypogonadism and its treatment among prostate cancer survivors.

Authors:  Edward J Choi; Perry Xu; Farouk M El-Khatib; Linda M Huynh; Faysal A Yafi
Journal:  Int J Impot Res       Date:  2020-12-12       Impact factor: 2.896

5.  Androgen replacement therapy after prostate cancer treatment.

Authors:  Mohit Khera
Journal:  Curr Urol Rep       Date:  2010-11       Impact factor: 3.092

Review 6.  Androgens, aging, and prostate health.

Authors:  Karin Welén; Jan-Erik Damber
Journal:  Rev Endocr Metab Disord       Date:  2022-06-24       Impact factor: 6.514

7.  Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer.

Authors:  Eric K Oermann; Simeng Suy; Heather N Hanscom; Joy S Kim; Sue Lei; Xia Yu; Guowei Zhang; Brook Ennis; Joyann P Rohan; Nathaniel Piel; Benjamin A Sherer; Devin Borum; Viola J Chen; Gerald P Batipps; Nicholas L Constantinople; Stephen W Dejter; Gaurav Bandi; John Pahira; Kevin G McGeagh; Lucile Adams-Campbell; Reena Jha; Nancy A Dawson; Brian T Collins; Anatoly Dritschilo; John H Lynch; Sean P Collins
Journal:  J Hematol Oncol       Date:  2011-03-27       Impact factor: 17.388

8.  Diagnosis and treatment of sexual dysfunctions in late-onset hypogonadism.

Authors:  Jin Wook Kim; Du Geon Moon
Journal:  Korean J Urol       Date:  2011-11-17

Review 9.  Testosterone therapy in men with prostate cancer: literature review, clinical experience, and recommendations.

Authors:  Abraham Morgentaler; William P Conners
Journal:  Asian J Androl       Date:  2015 Mar-Apr       Impact factor: 3.285

10.  Effects of Korean Red Ginseng extract on busulfan-induced dysfunction of the male reproductive system.

Authors:  Seok-Won Jung; Hyeon-Joong Kim; Byung-Hwan Lee; Sun-Hye Choi; Hyun-Sook Kim; Yang-Kyu Choi; Joon Yong Kim; Eun-Soo Kim; Sung-Hee Hwang; Kwang Yong Lim; Hyoung-Chun Kim; Minhee Jang; Seong Kyu Park; Ik-Hyun Cho; Seung-Yeol Nah
Journal:  J Ginseng Res       Date:  2015-01-22       Impact factor: 6.060

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.